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doi:10.1016/j.jtcvs.2006.12.013bjective: Carcinoid of the lung is considered low-grade malignancy, and less
nvasive treatment may therefore be considered. We analyzed the long-term out-
ome of initial bronchoscopic treatment in patients with intraluminal bronchial
arcinoids.
ethods: Initial bronchoscopic treatment was applied to improve presurgical
ondition, to obtain tissue samples for proper histologic classification, and to
nable less extensive parenchymal resection. For intraluminal bronchial carci-
oid, complete tumor eradication with initial bronchoscopic treatment was
ttempted. High-resolution computed tomography in addition to bronchoscopy was
sed to determine intraluminal versus extraluminal tumor growth. Surgery followed
n cases of atypical carcinoid, residue, or recurrence.
esults: Seventy-two patients, 43 of them female, have been treated (median age 47
ears, range 16-80 years). Median follow-up has been 65 months (range 2-180
onths). Fifty-seven (79%) had typical carcinoids and 15 (21%) had atypical
arcinoids. Initial bronchoscopic treatment resulted in complete tumor eradication in
3 of 72 cases (46%), 30 typical and 3 atypical. Thirty-seven of 72 cases (51%), 11
typical, required surgery (2 for late detected recurrences). Two patients had
etastatic atypical carcinoid, 1 already at referral. Of the 6 deaths, 1 was tumor
elated.
onclusions: Initial bronchoscopic treatment is a potentially more tissue-sparing
lternative than immediate surgical resection in patients with intraluminal bronchial
arcinoids. For successful tumor eradication with initial bronchoscopic treatment in
entral carcinoids, assessment of intraluminal versus extraluminal growth may be of
uch more importance than histologic division between typical and atypical carci-
oid. Disease-specific mortality is low, and long-term outcome has been excellent.
mplementation of initial bronchoscopic treatment had no negative impact on
urgical treatment outcome.
ronchial carcinoid (BC) tumors, members of the neuroendocrine group of
tumors, comprise 2% to 5% of all primary lung tumors.1,2 Carcinoids are
classified as either typical carcinoid (TC) or atypical carcinoid (AC) ac-
ording to the classification criteria of Travis and colleagues,3 which are based o
etrospective analyses of specimens from surgical series. The fact that AC tends to
how more lymphatic and metastatic spread than does TC2,4-7 and the possibility o
ubmucosal and extraluminal tumor growth seem overwhelmingly to warrant im-
ediate surgery as the only acceptable alternative.2,8-11
Current knowledge of tumor biology and growth pattern and increased use of
inimally invasive techniques, however, have improved our understanding and
valuation of disease processes, enabling a more tailored approach for each indi-
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TSidual at risk and allowing tissue-sparing alternatives to
urgical intervention.6,12-14 Such a consideration within va-
ous oncology disciplines may allow optimal preservation of
uality of life without compromising outcome.15 Both im-
roved knowledge and technical innovations should lead to
ritical review of conclusions that were based on previous
linical data regarding BC. Compared with AC, TC has
xcellent 5- and 10-year survivals of 87% to 100% and 82%
o 87%, respectively, versus 56% to 75% and 25% to 59%,
espectively. Even in cases with positive lymph nodes, TC
nd, to a lesser extent, AC still have acceptable survivals:
or TC, 5-year survivals as great as 100%, and for AC,
-year survivals of 25% to 78% and 10-year survivals of
5% to 59%.3,4,8-11,16 These survival data are based 
urgically resected specimens without detailed information
f bronchoscopic findings.
On the basis of and encouraged by our previous experi-
nces17-19 regarding initial bronchoscopic treatment (IBT) 
entral airway tumors before surgical resection, we report here
he long-term outcome of our strategy regarding BC.
atients and Methods
atients first seen with BC in the central airway (wholly or
artially intraluminal BCs) in the period 1991 to 2005 were
rospectively entered in this study protocol after informed
onsent. At that time, the regulatory requirement from the
cientific committee was oral informed consent after full
nformation about the pros and cons of IBT strategy. Pa-
ients and family members were fully informed, especially
bout potential disadvantages of IBT relative to the standard
reatment, surgical resection. Our IBT strategy, which is
ased on best clinical practice, is shown in Figure 
onjunction with improvements in diagnostic and therapeu-
ic modalities, our strategy has also been evolving to current
se of state-of-the-art technologies.
All patients referred to our institution underwent IBT
ith propofol anesthesia, with both rigid and flexible bron-
hoscopes used to obtain the maximum amount of tissue for
roper histologic diagnosis, to improve patient condition in
ase of obstructive pneumonia, and to enable less extensive
esection whenever feasible. Clearance of the tumor was
ostly performed by mechanical removal and application of
d:YAG laser or electrocautery.20 Within 6 weeks afte
Abbreviations and Acronyms
AC  atypical carcinoid
BC  bronchial carcinoid
HRCT high-resolution computed tomography
IBT  initial bronchoscopic treatment
TC  typical carcinoidBT, high-resolution computed tomography (HRCT) was o
74 The Journal of Thoracic and Cardiovascular Surgery ● Aprin
erformed to determine intraluminal versus extraluminal
umor growth, with flexible bronchoscopy repeated to eval-
ate the IBT result. Because BC may be seen with postob-
tructive pneumonia, a clear distinction between intralumi-
al and extraluminal extension can only be properly made
nce postobstructive debris and atelectasis have been
leared. In cases of obvious extraluminal disease, atypical
istologic type, unsuccessful intraluminal treatment, or re-
urrence, surgical resection was performed for radical tumor
emoval with complete mediastinal lymph node dissection.
BT was considered successful when there was no sign of
esidual disease (by videobronchoscopy, biopsy, thin-slice
RCT images, and radial endobronchial ultrasonography).
epeated evaluation was then performed semiannually in
he first 2 years and annually up to 5 years. Beyond the fifth
ear, patients have been referred back to their pulmonolo-
ists for further yearly check-ups.
Some patients, treated before the introduction of HRCT,
ave been monitored with more traditional computed to-
ography with slice thickness of 5 mm. Currently, with
4-multidetector computed tomography, slice thickness is
.75 mm with 0.5-mm overlap, with additional viewing
ossibilities of multiplanar reconstruction and virtual bron-
hoscopy as well. Recent use of endobronchial ultrasonog-
aphy with a 20-MHz radial transducer enables us to detect
inute bronchial wall abnormalities on the submillimeter
igure 1. Initial bronchoscopic treatment (IBT) strategy in bron-
hial carcinoids. CR, complete response with no residual tumor
etected macroscopically (videobronchoscopy, high-resolution
omputed tomography, and endobronchial ultrasonography since
003) and microscopically (biopsy and brush specimens); AC,
typical carcinoid; BT, bronchoscopic treatment. Extraluminal
xtension assessed with high-resolution computed tomography.
umbers of patients in each arm of our strategy are also shown.rder.21
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G
TSThe definitive histologic diagnosis (TC vs AC) was based
n the maximum amount of tissue ultimately sampled. All
amples collected before 1998 were reclassified according to
he Travis classification.3 Surgery was always with systema
odal dissection, and the least extensive parenchymal resection
ad always been attempted.6,12
We also analyzed the number of patients from the ar-
hives of the Dutch Central Tumor Registry to compare the
umber of individuals registered with BC in the Netherlands
uring the same study period.
esults
eventy-two patients have been treated, with a median
ollow up as of August 2006 of 65 months (range 2-180
onths). Patient characteristics and symptoms at referral are
hown in Table 1. Relative to the total number of in
als with BC in the Netherlands in the registry crude data,
ABLE 1. Patients with bronchial carcinoid of the central
irways: Characteristics and symptoms at referral
Typical
carcinoid
Atypical
carcinoid
o. of patients 57 15
ex (No.)
Male 26 3
Female 31 12
ge (y, median and range) 47 (17-77) 44 (16-80)
moking status (No.)
Nonsmoker 24 7
Former smoker 24 7
Current smoker 9 1
resenting symptoms (No.)
Pneumonia 17 8
Hemoptysis 14 1
Both pneumonia and hemoptysis 1 0
Dyspnea 11 5
Persistent cough 6 1
Other 8 0
ABLE 2. Clinical outcome of patients with bronchial ca
ompletion surgery
istologic subtype No. Treatment Outcome
ypical 30 IBT CR
1 IBT Residual
26 CS CR
typical 3 IBT CR
1 IBT Metastatic disea
10 CS CR
1 CS Metastatic disea
BT, Initial bronchoscopic treatment; CR, complete response with no r
omputed tomography, and endobronchial ultrasonography since 2003) and
urgically resected specimens, which always included systematic lymph node dis
The Journal of Thoracic-
his study represents about 10% of the total BCs diagnosed
uring the entire study period.
Results of our bronchoscopic treatment strategy are shown
n Table 2 and Figure 1. After 1 (n  27), 2 (n  7), or 4 (n 
) IBT sessions, 35 patients had complete tumor eradication
nd were subjected to long-term follow-up. Of the remaining
7 patients, 35 underwent completion surgery; all were N0
tatus. We performed 12 lobectomies, 6 sleeve lobectomies, 10
ilobectomies, 1 sleeve bilobectomy, and 6 pneumonectomies.
n 2 cases, less extensive resections were enabled by IBT. One
atient, with postoperatively proven extraluminal extension,
equired emergency surgical resection for persistent hemor-
hage during IBT. In 30 cases, involvement of the bronchial
all or extension into the parenchyma was found, rendering
urgical resection necessary.
In 2 cases, complete tumor eradication by IBT was not
chieved: 1 patient refused surgery and is alive (follow-up
10 months); the other had metastatic disease at referral,
as therefore treated in a palliative setting, and is still alive
follow-up 27 months). Both are currently well without
ulmonary symptoms.
Two patients for whom yearly follow-up was stopped after
he fifth year had late detected recurrences and underwent
urgical resection at 103.5 and 115.5 months after IBT. These
atients were therefore eventually placed in the surgical group.
Currently, 33 patients still have complete remission after
BT (median follow-up 72.5 months, range 2-180 months).
BT in 3 patients obtained complete remission of what was
roven to be AC (4, 5, and 7 mitoses/2 mm2). Because
valuation did not show any residual disease, completion
urgery has so far been postponed. Follow-up has been 14 to
4.5 months. Follow-up figures for the different cohorts are
hown in Table 3A.
Six patients (6/72, 8%) have died. Four had TC and 1 had
C, with all dying of unrelated causes, except 1 with
etastatic AC who died of pneumonia (Table 3B).
Histologic classification comparing bronchoscopic sam-
les versus surgical specimens showed only 5 discordant
id after initial bronchoscopic treatment with or without
Alive Dead Remarks
26 4 All deaths unrelated
1 No symptoms and refused surgery
26 0
3 0 Complete eradication at first session
1 0 Metastatic disease at referral
9 1 Unrelated death
0 1 Pneumonia with liver metastases
l tumor detected macroscopically (videobronchoscopy, high-resolution
oscopically (biopsy and brush specimens) or by histologic confirmation ofrcino
se
se
esidua
micrsection, showing radical resection and N0 status; CS, completion surgery.
and Cardiovascular Surgery ● Volume 133, Number 4 975
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TSases. In 2 cases, mitotic index shifted from 0 to 2 mitotic
gures/2 mm2, in 1 from 1 to 3 mitotic figures/2 mm2, and
n the last 2 from 0 to 4 mitotic figures/2 mm2.
iscussion
urrent understanding of tumor growth and behavior with
egard to the development of local and distant disease has
nabled us to consider alternative strategies that are aimed
oward optimal outcome in terms of maximum preservation
f quality of life. Especially in dealing with clinically less
alignant tumor type and in light of increasing recognition
f the long lead time that may occur, one needs to reflect
nd remain vigilant to enable parenchyma-sparing resection
henever feasible.22 Although from an oncologic point 
iew surgery should be considered the criterion standard,
urgical bronchoplasty has been an accepted strategy in BC
reatment.6,12 In line with this, prevention of extensive -
enchymal resection is the aim of bronchoscopic treat-
ent.6,12,22,23 We have increasingly recognized the pote-
ABLE 3A. Follow-up of patients still alive in months from
arcinoid Treatment Outcome
ypical IBT (n  27) CR (n  26)
Residue (n  1)
CS (n  26) CR (n  25)
Recurrence (n  1)*
typical IBT (n  4) CR (n  3)
Metastatic (n  1)
CS (n  9) CR (n  8)
Recurrence (n  1)*†
BT, Initial bronchoscopic treatment; CR, complete response with no r
omputed tomography, and endobronchial ultrasonography since 2003) an
n surgical specimens all N0 with systematic nodal dissection always perf
fter fifth year, delayed detection of extraluminal tumor recurrence. †His
arcinoid at completion surgery.
ABLE 3B. Follow-up (survival) of deceased patients with
istologic type Treatment Outcome Foll
ypical IBT (n  4) CR (n  4)
typical CS (n  2) CR (n  1)
Metastatic (n  1)
BT, Initial bronchoscopic treatment; CR, complete response with no r
omputed tomography, and endobronchial ultrasonography since 2003) an
n surgical specimens all N0 with systematic nodal dissection always perform
76 The Journal of Thoracic and Cardiovascular Surgery ● Apriial of a comprehensive approach in fully exploiting the
dvantages of minimally invasive approaches, including
BT.17,18,24-27 Diligent and careful workup and follow-
ith state-of-the-art technologies are key for this new par-
digm. Technical advances have also improved the ability
o monitor intraluminal disease processes in the submilli-
eter range.17,18
According to our data, clinical bronchoscopic classi-
cation of carcinoids as intraluminal or extraluminal
ould become of more clinical importance than histologic
lassification per se.3 In this study, the former distincti
as crucial in determining treatment modality. As men-
ioned before, the Travis classification is based on retro-
pective analysis of surgical data and thus lacks any
nformation about tumor growth pattern. It is possible
hat all those cases represent a different cohort of neu-
oendocrine tumors, more likely located in the lung pa-
enchyma. We thus may be dealing with a different
atient cohort.
ial bronchoscopic treatment until August 2006
Follow-up (mo)
RemarksMedian Range
92 14-180
110 Refused surgery
66 16-172
103.5 Follow-up from IBT until CS
16 Follow-up from CS until
August 2006
14 14-74.5
27 Palliative BT
51.5 13-86.5
115.5 Follow-up from IBT until CS
18.5 Follow-up from CS until
August 2006
l tumor detected macroscopically (videobronchoscopy, high-resolution
roscopically (biopsy and brush specimens) or by radical resection judged
; CS, completion surgery. *Delayed completion surgery, protocol violation
ic type typical carcinoid at initial bronchoscopic treatment and atypical
chial carcinoids
p (mo) Cause of death Remarks
Metastatic sarcoma
Unknown
Cardiovascular
Pulmonary embolism Cardiovascular morbidity
5 Murdered
Pneumonia Died with liver metastases
l tumor detected macroscopically (videobronchoscopy, high-resolution
roscopically (biopsy and brush specimens) or by radical resection judgedinit
esidua
d mic
ormed
tologbron
ow-u
83
48
114
2
65.
47
esidua
d miced; CS, completion surgery.
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G
TSDiscrepancies in histologic classification between bron-
hoscopic and surgical specimens collected (n  5) did not
ave any impact on either treatment strategy or clinical
utcome. All specimens showed extraluminal growth, and
urgical resection was required.
Our current ability to evaluate tumors in the submillime-
er range enables us to execute the optimal strategy without
ignificant treatment delay that could affect outcome.17-19
There were only 2 cases with late detected recurrence,
pparently the result of incomplete removal of submucosal
isease by IBT. Despite a more than 4.5-year delay, how-
ver, the outcome would not have been different had sur-
ery been performed earlier. Furthermore, long-term
ollow-up showed only 1 death attributable to metastatic
C, indicating the low malignant potential of BC.
In practice, even if surgical resection is still considered
he only accepted strategy, initial bronchoscopic tissue sam-
ling for definite histologic typing should also be exploited
o eradicate intraluminal tumor mass completely. There is
hen ample time for rethinking and restaging before further
reatment is considered necessary.
Current analysis underscores the sophistication of noninva-
ive and minimally invasive techniques such as HRCT scans
nd bronchoscopic techniques, as shown in Figure 2. Alth
his is essentially discordant with our strategy, lately in some
atients with AC the tumors have been completely removed at
he IBT session and surgery has been postponed.
One recent study of TC treated bronchoscopically
howed encouraging long-term results.28 There have, how-
igure 2. Examples of tumoral extent assessment with bronchos-
opy and high-resolution computed tomography.ver, been no previous prospective clinical, practical, sys-
The Journal of Thoracicematic studies of the role of IBT in patients with intralu-
inal BC. One retrospective study2 mentioned data from
srael comprising 68% centrally located BCs that may re-
emble the cohort potentially suitable for the IBT approach.
n the basis of our findings of the central registry crude
ata, however, only 10% of the yearly average cases in the
etherlands have been referred to us. We may therefore
ssume that at least approximately 5% of all BC can be
reated solely with IBT, because referral bias by pulmonolo-
ists in The Netherlands cannot be ruled out. They may
ave excluded from referral all patients with known extralu-
inal and parenchymal BC lesions. These may represent the
ame cohort as studied by Travis and colleagues.3
In summary, our longitudinal data regarding the integra-
ion of IBT into the treatment of patients with BC in the
entral airway suggest a logical and feasible clinical prac-
ice that challenges all presumed objections that immediate
urgical resection is absolutely required and that any delay
ay compromise outcome. IBT strategy is therefore an
nderrecognized and potentially tissue-sparing approach
hat does not compromise outcome. Careful judgment of
ntraluminal versus extraluminal tumor growth is currently
easible, allowing timely recognition of patients who re-
uire surgical resection. Our long-term data underscore the
ow malignant potential of BC, with only 1 disease-specific
eath in our population. A large number of patients remain
live, and more detailed retrospective quality of life and
ost-effectiveness analyses are being performed.
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